| Literature DB >> 25070421 |
Bumki Kim1, Heekwang Park1, Lilibeth A Salvador2, Patrick E Serrano1, Jason C Kwan3, Sabrina L Zeller1, Qi-Yin Chen4, Soyoung Ryu1, Yanxia Liu4, Seongrim Byeon1, Hendrik Luesch5, Jiyong Hong6.
Abstract
Largazole is a potent class I selective histone deacetylase (HDAC) inhibitor. The majority of largazole analogues to date have modified the thiazole-thiazoline and the warhead moiety. In order to elucidate class I-specific structure-activity relationships, a series of analogues with modifications in the valine or the linker region were prepared and evaluated for their class I isoform selectivity. The inhibition profile showed that the C2 position of largazole has an optimal steric requirement for efficient HDAC inhibition and that substitution of the trans-alkene in the linker with an aromatic group results in complete loss of activity. This data will aid the design of class I isoform selective HDAC inhibitors.Entities:
Keywords: Class I histone deacetylase; HDAC inhibitor; Isoform selectivity; Largazole; Structure–activity relationship
Mesh:
Substances:
Year: 2014 PMID: 25070421 PMCID: PMC4135083 DOI: 10.1016/j.bmcl.2014.07.006
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823